Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas

NCT07097363 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT07097363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07097363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
December 7, 2025
Completion date
May 31, 2030
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma, burkitt lymphoma, diffuse large b-cell lymphoma, not otherwise specified, ebv-positive diffuse large b-cell lymphoma, not otherwise specified, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, primary mediastinal large b-cell lymphoma, t-cell/histiocyte-rich large b-cell lymphoma, transformed b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma to diffuse large b-ce